Loading

Commentary Open Access
Volume 6 | Issue 2 | DOI: https://doi.org/10.33696/immunology.6.193

Can Molecular Biomarkers be Utilized to Determine Appropriate Adjuvant Therapy in Early-Stage Non-Small Cell Lung Cancer (NSCLC)?

  • 1Division of Hematology-Medical Oncology, Upstate Cancer Center, SUNY Upstate Medical University, Syracuse, NY, USA
+ Affiliations - Affiliations

Corresponding Author

Prashanth Ashok Kumar, ashokkup@upstate.edu, wizardakp@ymail.com

Received Date: April 23, 2024

Accepted Date: May 14, 2024

Keywords

LACE Bio, Adjuvant chemotherapy, Early-stage NSCLC, Immunotherapy

Author Information X